Stewart Washer
Direktor/Vorstandsmitglied bei BOTANIX PHARMACEUTICALS LIMITED
Vermögen: 281 912 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Matthew Callahan | M | 51 |
Botanix Pharmaceuticals, Inc.
 Botanix Pharmaceuticals, Inc. BiotechnologyHealth Technology Botanix Pharmaceuticals, Inc. develops therapeutics for the treatment of serious skin diseases. Its products include BTX1503-Acne, BTX1308-Plaque Psoriasis, and BTX1204-Atopic Dermatitis. The company is headquartered in Plymouth Meeting, PA. | 18 Jahre |
| Vincent Ippolito | M | 65 |
Botanix Pharmaceuticals, Inc.
Botanix Pharmaceuticals, Inc. BiotechnologyHealth Technology Botanix Pharmaceuticals, Inc. develops therapeutics for the treatment of serious skin diseases. Its products include BTX1503-Acne, BTX1308-Plaque Psoriasis, and BTX1204-Atopic Dermatitis. The company is headquartered in Plymouth Meeting, PA. | 5 Jahre |
| Paul Wotton | M | 63 | 8 Jahre | |
| Roger Aston | M | 68 | 12 Jahre | |
| Oludare Odumosu | M | - | 5 Jahre | |
| Geoff Brooke | M | 68 | 5 Jahre | |
| Howie McKibbon | M | - | 5 Jahre | |
| Kilian Kelly | M | - | 10 Jahre | |
| Michael Winlo | M | - | 5 Jahre | |
| Paul R. Nemeth | M | - |
iCeutica, Inc.
 iCeutica, Inc. Pharmaceuticals: MajorHealth Technology iCeutica, Inc. manufactures pharmaceutical products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. This technology enables iCeutica to make significantly improved formulations of approved and development stage drugs, some of which have been shown in late stage clinical trials to work faster, at a lower dose or be delivered to the body by an alternative route. The company was founded by James Williams and Matthew Callahan in 2005 and is headquartered in Philadelphia, PA. | 13 Jahre |
| Darryl Maher | M | - | 4 Jahre | |
| Greg Hutchinson | M | - | 1 Jahre | |
| Timothy Slate | M | - | 8 Jahre | |
| Ravi Thadhani | M | - | 1 Jahre | |
| Daniel Pollock | M | 64 | 12 Jahre | |
| Bill Bosch | M | - |
Botanix Pharmaceuticals, Inc.
Botanix Pharmaceuticals, Inc. BiotechnologyHealth Technology Botanix Pharmaceuticals, Inc. develops therapeutics for the treatment of serious skin diseases. Its products include BTX1503-Acne, BTX1308-Plaque Psoriasis, and BTX1204-Atopic Dermatitis. The company is headquartered in Plymouth Meeting, PA. | - |
| John van der Wielen | M | - | 1 Jahre | |
| Phillip Hains | M | 64 | 11 Jahre | |
| Fiona Melanie Wood | M | - | 1 Jahre | |
| Susan Park | F | 49 | 1 Jahre | |
| Henry Bosch | M | - | 8 Jahre | |
| Janine Rolfe | F | - | 2 Jahre | |
| Suzanne Lipe | M | - | 5 Jahre | |
| Paul James Kelly | M | - |
Hatchtech Pty Ltd.
 Hatchtech Pty Ltd. Pharmaceuticals: MajorHealth Technology Hatchtech Pty Ltd. operates as pharmaceutical product company. It offers Xeglyze lotion that is head lice treatment. The company was founded by Vernon Morrison Bowles in 2001 and is headquartered in in Melbourne, Australia. | 14 Jahre |
| Jack Hoblitzell | M | - | 3 Jahre | |
| Jolanta Airey | M | - | 3 Jahre | |
| Anthony Robinson | M | - | 3 Jahre | |
| Alex McHenry | M | - | 8 Jahre | |
| Jeremy Fletcher | M | 70 |
iCeutica, Inc.
iCeutica, Inc. Pharmaceuticals: MajorHealth Technology iCeutica, Inc. manufactures pharmaceutical products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. This technology enables iCeutica to make significantly improved formulations of approved and development stage drugs, some of which have been shown in late stage clinical trials to work faster, at a lower dose or be delivered to the body by an alternative route. The company was founded by James Williams and Matthew Callahan in 2005 and is headquartered in Philadelphia, PA. | 13 Jahre |
| Osagie Imasogie | M | 62 | 5 Jahre | |
| John Tooke | M | 75 | 6 Jahre | |
| Peter Webse | M | 61 | 1 Jahre | |
| Clarence L. Young | M | 68 | 3 Jahre | |
| Gregor Maier | M | - | 10 Jahre | |
| Simon Panton | M | - | 15 Jahre | |
| Daniel Sharp | M | - | 2 Jahre | |
| Karen Smith | M | 56 | 3 Jahre | |
| Mohit Kaushal | M | 45 | 1 Jahre | |
| Nathan Burkey | M | 50 |
iCeutica, Inc.
iCeutica, Inc. Pharmaceuticals: MajorHealth Technology iCeutica, Inc. manufactures pharmaceutical products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. This technology enables iCeutica to make significantly improved formulations of approved and development stage drugs, some of which have been shown in late stage clinical trials to work faster, at a lower dose or be delivered to the body by an alternative route. The company was founded by James Williams and Matthew Callahan in 2005 and is headquartered in Philadelphia, PA. | 13 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Ross MacDonald | M | 66 | 11 Jahre | |
| Harry Karelis | M | 54 | 13 Jahre | |
| Simon Robertson | M | 64 | 11 Jahre | |
| John Chiplin | M | 66 | 8 Jahre | |
| Monique Cannon | F | - | 10 Jahre | |
| Robert E. T. Towner | M | 55 | 6 Jahre | |
| Lisa Gray | F | 59 |
iCeutica, Inc.
iCeutica, Inc. Pharmaceuticals: MajorHealth Technology iCeutica, Inc. manufactures pharmaceutical products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. This technology enables iCeutica to make significantly improved formulations of approved and development stage drugs, some of which have been shown in late stage clinical trials to work faster, at a lower dose or be delivered to the body by an alternative route. The company was founded by James Williams and Matthew Callahan in 2005 and is headquartered in Philadelphia, PA. | 11 Jahre |
| McCall Liddy | F | - |
iCeutica, Inc.
iCeutica, Inc. Pharmaceuticals: MajorHealth Technology iCeutica, Inc. manufactures pharmaceutical products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. This technology enables iCeutica to make significantly improved formulations of approved and development stage drugs, some of which have been shown in late stage clinical trials to work faster, at a lower dose or be delivered to the body by an alternative route. The company was founded by James Williams and Matthew Callahan in 2005 and is headquartered in Philadelphia, PA. | 6 Jahre |
| Graeme N. Stevens | M | - | 6 Jahre | |
| Daniel Christian Mahnert-Lueg | M | - |
Genesis Research & Development Corp. Ltd.
 Genesis Research & Development Corp. Ltd. Financial ConglomeratesFinance Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand. | 1 Jahre |
| Peter Vaughan | M | 40 | 5 Jahre | |
| Howard Digby | M | 57 | 2 Jahre | |
| Stephen Anastasiou | M | 67 | 11 Jahre | |
| Mara Gordon | F | - | 4 Jahre | |
| Joseph M. Baini | M | 58 | 2 Jahre | |
| Colin T. McDonald | M | - | 2 Jahre | |
| Timothy Oldham | M | - | 3 Jahre | |
| Jason Peterson | M | - | 7 Jahre | |
| Andrew John Hubert Gearing | M | - |
Genesis Research & Development Corp. Ltd.
Genesis Research & Development Corp. Ltd. Financial ConglomeratesFinance Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand. | 6 Jahre |
| Richmond Hopkins | M | - | 3 Jahre | |
| Patrizia Washer | M | - | - | |
| Lars Åke Alvar Lidgren | M | 81 | 16 Jahre | |
| Joachim von Roy | M | 79 |
Genesis Research & Development Corp. Ltd.
Genesis Research & Development Corp. Ltd. Financial ConglomeratesFinance Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand. | 5 Jahre |
| Lorraine Chiroiu | F | - |
AusBiotech Ltd.
 AusBiotech Ltd. Miscellaneous Commercial ServicesCommercial Services AusBiotech Ltd. operates as an Australian biotechnology membership company. The private company is based in Melbourne, Australia. and has subsidiaries in Australia. The company was founded by Liz Dallimore. Lorraine Chiroiu has been the CEO of the company since 2008. | 15 Jahre |
| Michael Thurn | M | - | 3 Jahre | |
| Adam James | M | - | 3 Jahre | |
| Leslie Wise | F | - | 3 Jahre | |
| Stephane Levy | M | - | 2 Jahre | |
| Alistair Vickery | M | - | 5 Jahre | |
| Qi Xiao Zhou | M | 54 | 11 Jahre | |
| David Atkins | M | - | - | |
| Amanda Soogun | F | - | 3 Jahre | |
| Kathryn Andrews | F | 57 | - | |
| Stephen Copulos | M | - | 4 Jahre | |
| Paul Eisen | M | 65 | - | |
| Graham Chin | M | 69 |
Genesis Research & Development Corp. Ltd.
Genesis Research & Development Corp. Ltd. Financial ConglomeratesFinance Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand. | - |
| Dominic J. Autelitano | M | - | 4 Jahre | |
| James McLean | M | - |
Genesis Research & Development Corp. Ltd.
Genesis Research & Development Corp. Ltd. Financial ConglomeratesFinance Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand. | 16 Jahre |
| David Kenley | M | - |
Xceed Capital Ltd.
 Xceed Capital Ltd. Chemicals: Major DiversifiedProcess Industries Xceed Capital Ltd. is engaged in the manufacture of pharmaceutical products. The company's business includes chemical segment which is a supplier of organo-boron compounds. Xceed Capital is headquartered in Perth, Australia. | - |
| Peter Francis | M | 68 |
Xceed Capital Ltd.
Xceed Capital Ltd. Chemicals: Major DiversifiedProcess Industries Xceed Capital Ltd. is engaged in the manufacture of pharmaceutical products. The company's business includes chemical segment which is a supplier of organo-boron compounds. Xceed Capital is headquartered in Perth, Australia. | - |
| Paul Hopper | M | 68 | 2 Jahre | |
| Eva O'Malley | F | - | - | |
| Gabriel Chiappini | M | - | - | |
| Fabio Pannuti | M | 55 | 2 Jahre | |
| Richard Peterson | M | 56 | 1 Jahre | |
| Nina Webster | M | - | 2 Jahre | |
| Simon Selimaj Sallka | M | 62 | 4 Jahre | |
| Nivedita Findlay | F | - |
Genesis Research & Development Corp. Ltd.
Genesis Research & Development Corp. Ltd. Financial ConglomeratesFinance Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand. | 6 Jahre |
| Ewe Poh Lim | F | - |
Genesis Research & Development Corp. Ltd.
Genesis Research & Development Corp. Ltd. Financial ConglomeratesFinance Genesis Research & Development Corp. Ltd. operates as a development stage company. Previously, it was a technology investment company that builds a broad therapeutic development platform targeting immune disorders and cancer and a novel single stranded gene silencing technology using the RNAi mechanism. The company was founded by James Douglas Watson in 1994 and is headquartered in Auckland, New Zealand. | - |
| Oliver Stevens | M | - | 2 Jahre | |
| David C. U'Prichard | M | 75 |
iCeutica, Inc.
iCeutica, Inc. Pharmaceuticals: MajorHealth Technology iCeutica, Inc. manufactures pharmaceutical products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. This technology enables iCeutica to make significantly improved formulations of approved and development stage drugs, some of which have been shown in late stage clinical trials to work faster, at a lower dose or be delivered to the body by an alternative route. The company was founded by James Williams and Matthew Callahan in 2005 and is headquartered in Philadelphia, PA. | 9 Jahre |
| Ian Griffiths | M | - |
Xceed Capital Ltd.
Xceed Capital Ltd. Chemicals: Major DiversifiedProcess Industries Xceed Capital Ltd. is engaged in the manufacture of pharmaceutical products. The company's business includes chemical segment which is a supplier of organo-boron compounds. Xceed Capital is headquartered in Perth, Australia. | - |
| Colin Burton Chapman | M | 75 | 4 Jahre | |
| Roy Robins-Browne | M | 77 | 14 Jahre | |
| Lynda Berne | F | - | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Australien | 82 | 87,23% |
| Vereinigte Staaten | 9 | 9,57% |
| Neuseeland | 7 | 7,45% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Stewart Washer
- Persönliches Netzwerk
